Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT-PAS
2025-524673-16-00Phase 2Authorised
- Sponsor
- Masaryk University
- Start
- Mar 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic faecal microbiota suspension in Autism Spectrum Disorder (ASD), sponsored by Masaryk University. Primary endpoint: Treatment response in ADOS-2 calibrated severity scores. Planned start Mar 2026; status: authorised.
02
Drugs
allogeneic faecal microbiota suspension
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2025-524673-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524673-16-00.